Renal-limited thrombotic microangiopathy after switching from bevacizumab to ramucirumab: a case report

BACKGROUND: It is well known that vascular endothelial growth factor (VEGF) inhibitors can cause proteinuria. The incidence of proteinuria is high for bevacizumab, a humanized monoclonal antibody directed against VEGF, but the range of proteinuria rarely becomes nephrotic (2.2% occurrence according...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamada, Ryo, Okawa, Takao, Matsuo, Ken, Suzuki, Makoto, Mori, Noriko, Mori, Kiyoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6329058/
https://www.ncbi.nlm.nih.gov/pubmed/30634936
http://dx.doi.org/10.1186/s12882-018-1194-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6329058/
https://www.ncbi.nlm.nih.gov/pubmed/30634936
http://dx.doi.org/10.1186/s12882-018-1194-9

Ejemplares similares